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ABSTRACT   
Pulmonary vascular endothelial function may be impaired by oxidative stress in endotoxemia-derived 
acute lung injury. Growing evidence suggests that endothelial-to-mesenchymal transition (EndMT) 
could play a pivotal role in various respiratory diseases; however, it remains unclear whether EndMT 
participates in the injury/repair process of septic acute lung injury. Here, we analyzed 
lipopolysaccharide (LPS)-treated mice whose total number of pulmonary vascular endothelial cells 
(PVECs) transiently decreased after production of reactive oxygen species (ROS), while the population 
of EndMT-PVECs significantly increased. NAD(P)H oxidase inhibition suppressed EndMT of PVECs. 
Most EndMT-PVECs derived from tissue-resident cells, not from bone marrow, as assessed by mice 
with chimeric bone marrow. Bromodeoxyuridine-incorporation assays revealed higher proliferation of 
capillary EndMT-PVECs. In addition, EndMT-PVECs strongly expressed c-kit and CD133. LPS 
loading to human lung microvascular endothelial cells (HMVEC-Ls) induced reversible EndMT, as 
evidenced by phenotypic recovery observed after removal of LPS. LPS-induced EndMT-HMVEC-Ls 
had increased vasculogenic ability, aldehyde dehydrogenase activity and expression of drug resistance 
genes, which are also fundamental properties of progenitor cells. Taken together, our results 
demonstrate that LPS induces EndMT of tissue-resident PVECs during the early phase of acute lung 
injury, partly mediated by ROS, contributing to increased proliferation of PVECs. 
 
Key words: acute lung injury; cell transformation; endothelial-to-mesenchymal transition; progenitor 
cells; reactive oxygen species  
INTRODUCTION 
    Acute lung injury (ALI) and its most severe manifestation, acute respiratory distress syndrome 
(ARDS) are life-threatening complication in critically ill patients (48, 51). The morbidity and mortality 
of moderate and severe ARDS remain high, ranging between 30 and 50%, despite improvements in 
critical care patients’ management and new technological developments (43). The leading cause of ALI 
is sepsis, and converging data suggest that endothelial activation and damage are hallmarks of ALI 
pathophysiology (39, 40, 50). There have been several clinical trials targeting aggressive factors 
correlated with the development of ALI, such as inflammatory cells and pro-inflammatory cytokines, 
but limited reports indicating validity and efficacy (35). Thus, a paradigm shift in treatment strategy is  
needed. A treatment strategy designed to protect vascular endothelial cells and pulmonary epithelial 
cells against injury, and/or enhancement of the tissue repair would be among the most promising.  
    Endotoxemia, a major cause of ALI, is produced by deposition of large amounts of LPS, a 
gram-negative bacteria endotoxin (20, 41, 45). During this process, though some of the endothelial 
cells undergo apoptosis, most of them survive (16). There have been many studies focused on 
endothelial cell death in endotoxemia, but little is known about the functional and molecular changes 
that occur in the surviving endothelial cells. We hypothesize that one of these innate strategies is 
endothelial-to-mesenchymal transition (EndMT). 
    EndMT is a process in which endothelial cells lose cell-to-cell contacts among them with polarity 
and undergo a dramatic remodeling of the cytoskeleton. EndMT is characterized by the following 
features: 1) loss of intracellular junctions and endothelial markers, 2) acquisition of mesenchymal 
markers, and 3) increased migratory and invasive properties (19). Growing evidence suggests that 
EndMT is enhanced or triggered by various factors including transforming growth factor β (TGFβ), 
hepatocyte growth factor, fibroblast growth factor and so on. TGFβ is likely to be the most potent 
among factors which induce EndMT (17, 19, 28). 
    EndMT has mainly been studied in the context of pathologic tissue fibrosis in organs such as lung, 
heart and kidney (22, 32, 52, 53). EndMT can also be adaptive, and important in development. It 
contributes to cardiac development and angiogenesis (3-5, 49). For instance, embryonic endothelial 
cells undergo EndMT, and the transition to mesenchymal cells expressing α-smooth muscle actin 
(α-SMA) contributes to the maturation of pulmonary veins and arteries (3, 4, 12). In angiogenesis, 
EndMT may be required for the vessel-guiding tip cells to lose intercellular junctions that allow them 
to delaminate from the existing vessel and acquire the migratory phenotype necessary for angiogenic 
sprouting (49).  
    Considering that activation and damage of pulmonary vascular endothelial cells (PVECs) are 
pathophysiological hallmarks of ALI, EndMT may contribute to the repair of vascular injury in ALI. 
    Indeed, recent study demonstrated that LPS induces a fibrotic-like phenotype in human umbilical 
vein endothelial cells (HUVECs) (16). This process was explained by EndMT, and it was reported to 
depend on NAD(P)H oxidase-dependent ROS production (16). Nevertheless, it has not been clearly 
demonstrated whether endotoxin evokes pulmonary vascular EndMT in acute lung injury. There are no 
good in vivo experimental model that prove the pathophysiological role of EndMT in septic acute lung 
injury. 
    In addition to these, we recently reported that lung tissue-resident endothelial progenitor cells 
(EPCs) contribute to pulmonary vascular repair after endotoxin-induced injury (27). We hypothesized 
that in the process of tissue repair, LPS-induced EndMT-cells may dedifferentiate into more progenitor 
cell-like phenotype. 
    In the present study, we examined how LPS-induced pulmonary vascular EndMT occurs in vitro 
and in vivo. Then, we elucidated the possible role of ROS, one of the key factors of ARDS, in the 
process of EndMT. We also identified the origin of EndMT cells in bone marrow (BM) chimeras 
generated using green fluorescent protein-95 (GFP-95) transgenic mice, and investigated its possible 
progenitor cell-like role. 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
Mouse model of septic lung injury 
    Seven- to eight-week-old female C57BL/6 mice (Clea Japan, Tokyo, Japan) were intraperitoneally 
administered 10 mg/kg body weight LPS derived from Escherichia coli (O55:B5 Sigma, St Louis, MO) 
dissolved in PBS. All animal experiments were conducted under protocols approved by the Review 
Board for animal experiments of Chiba University. 
  
Lung wet/dry weight ratio 
    After mice were euthanized, lungs were removed and wet weight was determined. Then, the lung 
tissue was placed in an oven at 60 °C for 24 hours to obtain dry weight. The ratio of wet to dry lung 
was calculated to assess the degree of tissue edema. 
 
Measurement of pulmonary vascular leakage  
    Leakage of protein from the pulmonary vasculature was assessed by measuring the accumulation 
of Evans Blue dye in the right lung. Evans Blue dye (30 mg/kg; Sigma-Aldrich) in sterile saline was 
injected via the tail vein. After 1 hour, the lungs were flushed with PBS, removed, and Evans Blue was 
extracted. Evans Blue was quantitated in a spectrophotometer by measuring absorbance at 620 nm as 
previously described (36). Evans Blue dye extravasation was expressed as ng Evans blue/mg dry tissue 
(9).   
 Lung histological analyses 
    Lungs were formalin fixed and embedded in paraffin. Sections (5 µm) were stained with 
hematoxylin and eosin (HE) for histological evaluation. 
 
Fluorescent immunohistochemistry 
    Lungs were embedded in OCT (SAKURA Finetek, Tokyo) and frozen in liquid nitrogen to 
prepare the cryosections. Frozen lung tissues were cut into 6-μm-thick sections, immunostained and 
visualized by confocal microscopy (Fluoview FV 10i, Olympus, Tokyo). The sections were fixed in 
acetone for 10 minutes, blocked with Block Ace (Dainippon Sumitomo Pharma, Tokyo) for 10 minutes, 
and incubated with the primary and secondary antibodies for 60-120 minutes. The following antibodies 
were used for immunostaining: anti-CD31-Alexa488 (BioLegend, San Diego, CA), anti-Ki67 
(BioLegend), anti-α-SMA (Thermo Scientific, Waltham, MA), anti-CD133 (eBioscience, San Diego, 
CA), and anti-CD117 (eBioscience). We separated vessels by diameter and morphology to determine 
the location of EndMT-PVECs; those less than 5 μm in diameter and flattened were defined as 
“capillary” vessels. 
 
Human pulmonary vascular endothelial cell injury model 
    Human lung microvascular endothelial cells (HMVEC-L) were purchased from Clonetics 
(Walkersville, MD), and were cultured in endothelial cell basal medium-2 (EBM-2, Lonza, 
Walkersville, MD) supplemented with 10% fetal bovine serum and endothelial cell growth medium 2 
(EGM-2 SingleQuots, Invitrogen, Carlsbad, CA). All cells were maintained at 37 °C in a 5% CO2 
humidified incubator. Cells were cultured to 90% confluence and transitioned to starvation medium 
including EBM-2 supplemented with 1% fetal bovine serum, 0.1% gentamicin sulfate and 
amphotericin-B, heparin and ascorbic acid for 24 hours. Cells were exposed to vehicle (PBS) or LPS 
(10µg/ml) in fresh starvation medium at 37 °C for 1, 2, 4, 6, 48, 96, 144 hours.  
 
Lung single cell suspension 
    At the time of harvest, the lungs were perfused blood free with 30 ml PBS containing 10 U/ml 
heparin (Novo-Heparin, Mochida, Tokyo) from the right ventricle, then minced and digested in an 
enzyme cocktail of DMEM (Sigma) containing 1% of BSA (Wako, Osaka, Japan), 2 mg/ml of 
collagenase (Wako), 100 µg/ml of DNase (Wako), and 2.5 mg of Dispase II (Roche Diagnostics GmbH, 
Mannheim, Germany) at 37 °C for 60 minutes, then meshed through a 100 µm nylon cell strainer. 
 
Flow cytometry (FCM) of lung cells 
    Mouse lung cells were pretreated with anti-CD16/32 antibody (BioLegend) to block Fc receptors, 
and then incubated with specific antibodies at 4°C in the dark. The following antibodies were used for 
cell surface staining: anti-CD31-PE/Cy7 (BioLegend), anti-CD45-Alexa700 (BioLegend), 
anti-CD11b-FITC (BioLegend), anti-Ly-6G/Ly-6C (Gr-1)-Alexa647 (BioLegend), anti-CD34 
(BioLegend), anti-CD133 (eBioscience), anti-CD117/c-kit-PE (BioLegend) and streptavidin-PE 
antibodies (BioLegend). To assess DNA degradation, the cells were incubated with 10 μg/ml of 
Hoechst 34580 (Life Technologies, Grand Island, NY) for 30 minutes at 37 °C in the dark. To detect 
proliferating cells, bromodeoxyuridine (BrdU) APC flow kit (BD Pharmingen, San Diego, CA) was 
used for staining intracellular BrdU according to the manufacturer’s protocol. Regarding measurement 
of α-SMA and S100 calcium-binding protein A4 (S100A4), after surface staining the cells were 
incubated with anti-α-SMA (Thermo Scientific) and anti-S100A4 (Abcam, Cambridge, UK) for 35 
minutes at 22ºC. The secondary antibody used was a donkey anti-rabbit IgG-Alexa 488 (IgG; H+L) 
(Life Technologies) for 25 minutes at 22ºC.  
    HMVEC-Ls were pretreated with anti-CD16/32 antibody, and then incubated with the following 
reagents: anti-CD31, -CD45, and -α-SMA. Cell fluorescence was measured using FACSCantoTM II 
instrument (Becton Dickinson, San Jose, CA) and analyzed employing FlowJo software (Tree Star, San 
Carlos, CA).  
 
Isolation of mouse PVECs 
    Mouse PVECs were defined as CD31
+
/CD45
-
 cells. Lung cells were incubated with anti-CD16/32 
antibody (BioLegend), and then with anti-CD31-FITC (BioLegend) and anti-CD45-PE (BioLegend). 
For sorting CD31
+
/CD45
-
 cells, the cells were incubated with anti-PE microbeads (Miltenyi Biotec, 
Auburn, CA) for 15 minutes at 4 °C in the dark, and CD45
+
 cells were depleted through once in deplete 
mode of autoMACSTM or autoMACSTM Pro Separator (Miltenyi Biotec). Then the remaining cells 
were incubated with anti-FITC microbeads (Miltenyi Biotec) for 15 minutes at 4 °C in the dark, and 
CD31
+
 cells were sorted through twice in positive selection mode. 
 
Fluorescent immunocytochemistry (ICC) 
    Isolated mouse PVECs were fixed in a 1:1 mixture of methanol and acetone for 2 minutes 
followed by blocking with normal goat serum for 30 minutes as described previously (44). The cells 
were incubated with primary antibodies (anti-α-SMA, anti-S100A4 and anti-CD31) for 1 hour at room 
temperature, and then with secondary antibodies for 1 hour at room temperature. Finally, Hoechst 
34580 (Sigma) was used to identify the cell nuclei, and the cells were examined by confocal 
microscopy (Fluoview FV 10i, Olympus). HMVEC-Ls cultured with or without LPS for 144 hours 
were immunostained using the same method. 
 
qRT-PCR analysis 
    Total RNA from CD31
+
/CD45
-
 cells was isolated with Nucleo Spin RNA XS (MACHEREY 
NAGEL GmbH & Co. KG, Diiren, Germany) according to the manufacturer’s instructions. RNA was 
subjected to RT-PCR with SuperScript VILO (Life Technologies) according to the manufacturer’s 
protocol and single stranded cDNA was synthesized. The resultant cDNA samples were subjected to 
PCR for amplification using an ABI Prism 7300 Sequence Detection System (Applied Biosystems, 
Carlsbad, CA). Specific primers and probes were designed using the web software of Universal 
ProbeLibrary Assay Design Center (Roche Applied Science). The Ct value of each sample was 
normalized with Hprt1 as the endogenous control gene and the relative expression level was calculated 
using the 2-ΔΔCt method.  
 
ROS generation assay 
    After surface staining, the cells were incubated in PBS containing 40 µM of dichlorofluorescein 
diacetate (DCFDA; Life Technologies) or 5 µM CellRox Deep Red (Life Technologies) for 30 minutes 
at 37°C, to measure intracellular ROS. 
 
Tube formation assay 
    Isolated PVECs suspended in EBM-2 (Lonza) supplemented with single aliquots of 10% FBS 
EGM-2 MV (Lonza) were seeded at a cell density of 4x10
5
 cells/well into 200 µl/well MatrigelTM 
(BD) coated chamber slides. These were examined for network formation under microscope. 
 
BM reconstitution 
    Donor BM cells were obtained from the femoral and peroneal bones of transgenic mice that 
expressed enhanced GFP under control of CAG promoter (GFP-transgenic mice; Japan SLC, Shizuoka). 
On the same day, recipient wild type female mice (5weeks old) were irradiated with 5 and 4.5 Gy with 
an interval of 3 hours and transplanted by injection of the donor BM cells (1.0 × 10
7
 cells in 200 μl 
PBS) through the tail vein. 
 
NAD(P)H oxidase inhibition 
    Apocynin (10mg/kg
-1
/day, i.p.) (Sigma, St Louis, MO) or diphenyleneiodonium sulfate (DPI; 
Toronto Research Chemicals, Toronto, ON, Canada) (1mg/kg
-1
/day, s.c.) was administered to treated 
mice in vivo. In in vitro experiments, cells were treated with apocynin (300µM). 
 
TGFβ inhibition 
    LY364947 (Sigma, 1mg/kg
-1
/day, i.p.) was administered to treated groups in vivo. In in vitro 
experiments, cells were treated with LY364947 (2µM). 
 
Euk-134 treatment 
    For treatment in vivo with the superoxide dismutase (SOD) and catalase mimetic Euk-134, mice 
were given 10 mg/kg Euk-134 (Cayman Chemical, Ann Arbor, MI) in normal saline once daily 
intraperitoneally. 
 
Statistical analysis 
    Values are shown as mean ± SEM unless otherwise described, or median (25–75th percentile). The 
results were analyzed using the Mann-Whitney test for comparison between any two groups, and by 
nonparametric equivalents of ANOVA for multiple comparisons. GraphPad PRISM software (Version 
6.03; GraphPad Software, San Diego) was used to analyze the data. The level of statistical significance 
was set at P <0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Transient decrease of the total number of PVECs was associated with increased apoptosis 
    Mice challenged with intraperitoneal LPS, showed a decrease of body weight until day 2 (Fig. 1A) 
and development of protein-rich pulmonary edema until day 2 (Fig. 1B, C).  
    Intraperitoneally injected LPS induced a marked influx of leukocytes (CD31
-
/CD45
+
 cells) 
including neutrophils (Gr-1
+
/CD11b
+
/CD31
-
/CD45
+
 cells) into the lungs (Fig. 1D-F). The influx of 
inflammatory cells was confirmed by HE staining (Fig. 1F).       
    The total number of PVECs (CD31
+
/CD45
-
 cells) decreased significantly by day 2 (median; 
30.2% decrease), but recovered by day 7 (Fig. 1D, G). Hoechst 34580 staining revealed an increase in 
apoptotic PVECs with fragmented DNA from day 1 to day 2, and a decrease thereafter (Fig. 1H, I).  
 
Reactive oxygen species in PVECs transiently increased antecedant to apoptosis 
    Oxidative stress plays a significant role in the development of acute lung injury (10). Therefore, 
we determined the amount of intracellular ROS in PVECs by FCM analysis using DCFDA and 
CellRox Deep Red, both of which are well-known quantitative markers of cellular oxidative stress (11). 
Following LPS challenge, Both DCFDA and CellRox Deep Red geometric mean fluorescence intensity 
significantly increased within 12 hours (1.9-fold) and then gradually decreased from day 2 until day 7 
(Fig. 1J, K). ROS production preceded the increase in PVEC apoptosis, which began to increase on day 
1. 
 Pulmonary vascular EndMT increased during PVECs injury in vivo 
    Recent reports have indicated that LPS induces a fibrotic phenotype in HUVECs (15, 16). Thus 
we evaluated whether EndMT occurred in PVECs after LPS challenge in vivo.  
    We defined the PVECs that underwent EndMT (EndMT-PVECs) as those showing 
double-labeling with antibodies against CD31 and α-SMA, or with antibodies against CD31 and 
S100A4 (15-17). Changes in the number of EndMT-PVECs after LPS challenge are shown in Figure 
2A. Representative panels of FCM analyses are shown in Figure 2B. There was a significant increase in 
the number of PVECs expressing α-SMA (α-SMA+PVECs) and S100A4 (S100A4+PVECs) on day 2 
(Fig. 2A, B), while the total number of PVECs significantly decreased (Fig. 1G). We isolated 
endothelial cells (CD31
+
/CD45
-
 cells) using magneto-beads, and performed ICC experiments. As 
shown in Figure 2C, a significant increase of EndMT-PVECs (CD31
+/α-SMA+ cells and 
CD31
+
/S100A4
+
 cells) was detected on day 2 after LPS challenge. Quantitative RT-PCR analyses of 
the isolated PVECs showed that LPS-PVECs expressed less endothelial cell markers such as Pecam1, 
Cdh5 and Vwf on day1 (Fig. 2D), more mesenchymal cell markers such as Col1a1, Col1a2, S100a4, 
Vim and Myh11 on day2 (Fig. 2D), and more transcriptional factors related to EndMT such as Snai1, 
Snai2, Twist1, Twist2, and Zeb1 on day2 (Fig. 2D). 
 
Characterization of EndMT-PVECs 
   Proliferation of EndMT-PVECs 
    To examine the proliferative characteristics of EndMT-PVECs, we performed BrdU incorporation 
experiments. FCM analyses revealed significantly higher percentages of BrdU-positive α-SMA+PVECs 
compared with α-SMA-PVECs on day 2 of LPS challenge (Fig. 3A). Immunofluorescent histological 
analyses also revealed the presence of α-SMA+ cells on day 2 of LPS-induced injury in capillary 
vessels where smooth muscle cells are usually absent (Fig. 3B). These cells co-expressed CD31, 
indicating they corresponded to EndMT-PVECs (Fig. 3B). In addition, most EndMT-PVECs expressed 
Ki67, a marker of cell proliferation (Fig. 3B). Subsequently, the number of proliferative (Ki67
+
) PVECs 
per 50 PVECs was compared between α-SMA+- and α-SMA--PVECs. As shown in Figure 3C, few 
proliferative cells were observed among α-SMA-PVECs, whereas the number of proliferative cells 
among α-SMA+PVECs was significantly increased (α-SMA-PVECs vs. α-SMA+PVECs: 2.3 ± 1.2 cells 
vs. 23.7 ± 5.0 cells, P <0.05) (Fig. 3C). 
 
   Cell surface markers of progenitor cells 
    We compared expression of cell surface markers of progenitor cells on non-EndMT- (α-SMA--) 
and EndMT- (α-SMA+-) PVECs on day 2 of LPS challenge. CD133 and c-kit expression was higher in 
EndMT-PVECs (Fig. 3D). Representative panels of FCM analyses are shown in Figure 3E. These flow 
cytometric data corresponded well to the results of immunofluorescence analyses with double staining 
for α-SMA and progenitor cell-markers such as CD133 (Fig. 3F) or c-kit (Fig. 3G). Taken together, 
these results indicated that EndMT may not only be a direct transformation to mesenchymal cells, but 
also a dedifferentiation to progenitor-like cells (34).  
 
   The majority of EndMT-PVECs originated from tissue-resident cells 
    To determine the origin of EndMT-PVECs observed after LPS challenge, we used mice 
reconstituted with GFP-expressing (GFP
+
) BM cells to distinguish BM-derived from non-BM derived 
(GFP
-
) cells (Fig. 4). More than 12 weeks after BM reconstitution, the percentage of GFP
+
 cells in 
peripheral blood cells, lung interstitial leukocytes and PVECs of the recipients (Fig. 4A-C) was 96.8 ± 
1.6 % (n = 30), 85.5 ± 1.8 % (n = 3) and 0.83 ± 0.92 % (n = 3), respectively. After LPS administration, 
the percentage of GFP
+
 in PVECs transiently increased on day 2 (day 0 vs. day 2 vs. day 7: 1.08 ± 
0.32 % vs. 5.72 ± 0.43 % vs. 1.46 ± 0.16 %; Fig. 4D). Representative panels of FCM analyses are 
shown in Figure 4E. However, the percentage of GFP
+
 in α-SMA+PVECs did not increase significantly. 
The percentage on days 0, 2 and 7 of LPS challenge (Fig. 4F) was 0.83 ± 0.92%, 1.25 ± 1.18% and 
0.91 ± 1.13%, respectively, indicating tissue-resident GFP
-
PVECs continued to significantly 
predominate during the follow up term after LPS challenge. These results indicated that most of the 
new EndMT-PVECs originated not from BM derived cells, but from tissue-resident endothelial cells. 
Representative panels of FCM analyses are shown in Figure 4G. 
 
LPS-induced EndMT via NAD(P)H oxidase-dependent ROS production 
    TGFβ is a key inducer of EndMT, though little is known about other signaling events that trigger 
EndMT. Since LPS-induced EndMT-PVECs was associated with an increase of ROS production, we 
tested whether LPS-induced EndMT was mediated by oxidative stress. As excessive production of ROS 
by NAD(P)H oxidase is responsible for tissue injury associated with respiratory inflammatory 
diseases/injuries including ARDS (30), we injected apocynin intraperitoneally or DPI subcutaneously 
to C57BL/6 mice to block NAD(P)H oxidase activation. In addition, to confirm the importance of other 
source of ROS in EndMT, we tested Euk-134, which mimics the catalytic function of SOD coupled 
with catalase. We also used LY364947, which is a selective inhibitor of TGFβ receptor type I (TGFβRI), 
to evaluate the role of TGFβ and ROS in EndMT. 
 
   Inhibition of TGFβ signaling attenuated ROS production and EndMT in PVECs 
    Intracellular ROS measured ex vivo in PVECs isolated by FCM analysis using DCFDA and 
CellRox Deep Red significantly decreased in LPS-PVECs treated with LY364947, a TGFβ inhibitor 
(Fig. 5A, B). In addition, LY364947 significantly attenuated pulmonary vascular EndMT, which was 
confirmed by a significant decrease in CD31
+/α-SMA+ cells and CD31+/S100A4+ cells (Fig. 5C, D). 
We also evaluated EndMT-associated gene expression in PVECs. This revealed that LY364947 
attenuated EndMT at the level of gene expression (Fig. 5E). These results indicated that inhibition of 
the TGFβ pathway attenuates production of both ROS and EndMT in PVECs. 
 
   Inhibition of NAD(P)H oxidase attenuated EndMT and expression of Tgfb1 and Tgfb2 
transcripts in PVECs 
    As expected, the expression of ROS was significantly decreased in LPS-PVECs treated with 
apocynin, DPI or Euk-134 (Fig. 5A, B). Apocynin and DPI significantly attenuated pulmonary vascular 
EndMT, which was confirmed by a significant decrease in CD31
+/α-SMA+ cells and CD31+/S100A4+ 
cells (Fig. 5C, D). Interestingly, NAD(P)H oxidase inhibitors attenuated Tgfb1 and Tgfb2 gene 
expression, implying an interaction between ROS and the TGFβ pathway (Fig. 5E). In addition, 
NAD(P)H oxidase inhibition attenuated EndMT as assessed by transcription of EndMT-related genes 
(Fig. 5E). Euk-134 also slightly attenuated EndMT, though not statistically significant (Fig. 5C, D). 
These results indicated that LPS-induced EndMT is closely affected by NAD(P)H oxidase-dependent 
ROS production. 
 
LPS induced EndMT of HMVEC-Ls in the absence of immune cells 
    Clinical and experimental studies have provided circumstantial evidence of neutrophil-mediated 
inflammation in acute lung injury (48), still acute lung injury does develop in patients with profound 
neutropenia. Thus, we next tested whether LPS induced pulmonary vascular EndMT in the absence of 
immune cells in vitro.   
    LPS exposure induced morphological change to a spindle-shaped phenotype (Fig. 6A). ICC 
analyses revealed that LPS treatment increased α-SMA+HMVEC-Ls (Fig. 6B). These findings imply 
that EndMT was reproducible in vitro. FCM analyses also revealed that LPS treatment induced an 
increase of α-SMA-expression onto HMVEC-Ls (Fig. 6C). FCM analyses using DCFDA revealed that 
LPS exposure increased ROS generation in HMVEC-Ls prior to the increase of EndMT (Fig. 6D). 
    Expression of ROS was significantly decreased in LPS-treated HMVEC-Ls treated with inhibitors 
of NAD(P)H oxidase (apocynin) and TGFβRI (LY364947) (Fig. 6D). EndMT was suppressed by 
NAD(P)H oxidase inhibitor or the TGFβRI inhibitor, which was confirmed by FCM (Fig. 6E) and 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) (Fig. 6F-H). 
    These results indicated that LPS provokes EndMT of HMVEC-Ls even in the absence of immune 
cells, mediated by simple ROS generation. 
 
Long term exposure to LPS induced a higher EndMT response in vitro 
    As shown in Figure 6D, ROS generation in HMVEC-L reached its maximum level at 2 hours after 
the start of LPS exposure and then gradually decreased. Since we could not evaluate the effect of long 
term exposure to LPS in vivo due to high mortality, we tested it using HMVEC-Ls. For maintenance its 
concentration, LPS containing media were replaced every 48 hours.  
    As shown in Figure 7A and B, the percentage of α-SMA+HMVEC-Ls reached about 50% at 96 
hours, and reached a plateau thereafter. When LPS was removed from media at 96 hours, the 
percentage of α-SMA+HMVEC-Ls significantly decreased at 144 hours (not removal vs. removal: 46.6 
± 2.41 % vs. 10.3 ± 4.95 % ; P <0.05). This indicated that most of the phenotypic change was 
reversible, or so-called 'partial EndMT,' while the rest of the irreversible phenotypic change was 
'complete EndMT' (49).  
 
EndMT-HMVEC-Ls showed several characteristics of progenitor cells 
    Since our results in vivo showed EndMT-PVECs were highly capable of proliferation and 
expressed markers of putative progenitor cells such as Prom1/CD133 and c-kit when the total number 
of PVECs decreased in lung injury, we speculated that most of EndMT-PVECs behaved as 
progenitor-like cells in a process critical to lung injury repair. To confirm this, we conducted the 
following experiments using HMVEC-Ls that exhibited a higher EndMT response after long term (144 
hours) exposure to LPS. 
 
   Gene expression of progenitor cells and proliferation marker in EndMT-HMVEC-Ls 
    We first examined whether LPS-treated HMVEC-Ls, about 50% of which co-expressed α-SMA, 
showed enhanced expression of putative progenitor genes: PROM1/CD133, KIT and CD34. Among 
these genes, PROM1/CD133 and KIT were significantly increased in EndMT-HMVEC-Ls (Fig. 7C).  
    Given that proliferative ability is a crucial factor of progenitor cells, we next examined the gene 
expression of MKI67, a marker of proliferation by quantitative PCR analyses of EndMT-HMVEC-Ls. 
As shown in Figure 7D, a significant increase of MKI67 was observed in EndMT-HMVEC-Ls 
(5.4-fold), which supported the result of BrdU-incorporation assay in vivo. 
    Expression of drug resistance genes in EndMT-HMVEC-Ls 
    Because several ATP-binding cassette (Abc) transporter genes, which are associated with the 
efflux of noxious reagents from the cells, have been used as functional markers of stem/progenitor cells 
(27, 47), we examined the expression of three Abc transporter genes. Figure 7E shows that the 
expression of ABCB1 significantly increased in EndMT-HMVEC-Ls (2.1-fold), suggesting the survival 
potential of EndMT-HMVEC-Ls in acute lung injury. 
 
   Aldehyde dehydrogenase (ALDH) activity of EndMT-HMVEC-Ls 
    ALDH activity has been reported to increase in stem/progenitor cells (25, 29). We analyzed two 
genes related to ALDH activity (25). The expression of ALDH1B1 significantly increased in 
EndMT-HMVEC-Ls (2.7-fold) (Fig. 7F). 
 
   Vasculogenic capacity of EndMT-HMVEC-Ls 
    Increased vasculogenesis is one of the fundamental properties of progenitor cells (2, 18, 46); 
therefore we performed tube formation assays on Matrigel
TM
-coated chamber slides using HMVEC-Ls 
subjected or not to LPS challenge (Fig. 7G). LPS-treated HMVEC-Ls, about 50% of which 
co-expressed α-SMA (EndMT-HMVEC-Ls), began to form tube-like networks from day 1 and this was 
expanded until day 7. In contrast, HMVEC-Ls that were not subjected to LPS challenge exhibited very 
short tubular structure on day 7. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
    In this study, we first demonstrated that pulmonary vascular EndMT occurred in a murine model 
of endotoxin-induced lung injury. While LPS induced apoptosis in pulmonary endothelial cells in vivo, 
survived endothelial cells underwent mesenchymal transition from the early phase of acute lung injury. 
We also determined that ROS, a major cause of acute lung injury, directly induced EndMT in 
pulmonary endothelial cells, which was significantly blocked by NAD(P)H oxidase. Importantly, 
LPS-induced EndMT-PVECs expressed progenitor cell markers and showed increased cell proliferation 
ability and angiogenesis. 
    Acute lung injury is characterized by substantial oxidative stress in the lung, which leads to 
cellular injury and disease (10). Our experiment in vivo showed that the increase of intracellular ROS 
in PVECs was followed by an increase of EndMT-PVECs. This suggested that ROS has a driving 
potential for EndMT and we proved this by administering two different antioxidants which block 
NAD(P)H oxidase, a major source of superoxide in vascular endothelial cells (14, 21). As far as we 
know, this is the first study demonstrating that oxidative stress mediates LPS-induced pulmonary 
vascular EndMT in vivo. Interestingly, TGFβ might increase ROS production and ROS might 
activate/induce TGFβ in LPS-induced acute lung injury. Although we did not show the synergism 
between the antioxidants and the TGFβRI inhibitor in vascular EndMT in this study, the two likely 
interact. The endotoxemia generated by LPS induces a burst of other pro-inflammatory cytokines such 
as tumor necrosis factor-α and interleukin-6. These pro-inflammatory cytokines also might be involved 
in EndMT in acute lung injury (33, 37). 
    Endotoxin-induced vascular injury of the lung occurs mainly at the peripheral capillary level, 
interstitial leaked fluid blocks the diffusion capacity leading to progressive respiratory failure (13, 24). 
In the acute phase of acute lung injury, EndMT could contribute to the angiogenic repair of injured 
PVECs. Indeed, EndMT-PVECs were increased in capillary vessels on day 2 after LPS challenge, 
showed high proliferative potential and expressed endothelial progenitor cell (EPC) markers such as 
CD133 and c-kit. Recently, it has become evident that some forms of cells, recruited from the bone 
marrow and from some other tissues, circulate in the peripheral blood and have the ability to be 
embedded in the injured endothelium and differentiate into mature cells with endothelial characteristics. 
These cells were called EPCs, and they seemed to be an important mechanism for maintenance and 
repair of the endothelium (7, 8, 26, 42). Our experiments in vitro also showed that EndMT cell-rich 
HMVEC-Ls had higher vasculogenic capacity, expression of drug resistance genes and ALDH activity, 
which strongly suggested that EndMT-PVECs include functional EPCs. 
    In previous studies we have shown that pulmonary microvascular endothelial cells were enriched 
with progenitor cells that had vasculogenic capacity (27, 38). LPS-induced EndMT-PVECs occurred at 
the capillary level where tissue-resident EPCs also located (27, 38). Although it has been reported that 
the expression of mesenchymal progenitor cell markers is up-regulated during the process of EndMT, 
our findings suggested the possibility that some survived pulmonary endothelial cells underwent 
EndMT to dedifferentiate towards endothelial progenitor-like cells, contributing thereby to the 
replacement of the injured endothelium. The endothelium itself is believed to have a relatively weak 
capacity for self-repair, because it is built from mostly terminally differentiated cells with low 
proliferative capacity (1). However, our study suggests that mature endothelial cells surrounding the 
injured locus in the endothelium can replicate in situ and replace lost and damaged cells via EndMT. 
    In addition, we investigated the origin of LPS-induced EndMT-PVECs in vivo. To do so, we used 
BM-chimera mice to distinguish tissue-resident from BM-derived circulating cells. Setting time as 3 
months between BM transplantation and LPS challenge enabled us to establish about 95% chimerism 
of peripheral blood cells (27), avoiding underestimation due to insufficient BM reconstitution; lung 
interstitial leukocytes were efficiently replaced by BM-derived cells, while about 98% of 
EndMT-PVECs were non-BM-derived cells before and after LPS challenge. These results indicated 
that the majority of EndMT-PVECs originated from tissue-resident PVECs, not from the bone marrow. 
To our knowledge, this study is the first to describe the origin of EndMT-PVECs. Accumulating 
evidence has demonstrated that BM-derived endothelial progenitor cells are involved in tissue repair (6, 
7). However, the sources of these cells are matter of debate, i.e. from bone marrow or from the tissue 
resident cells, especially in lung injury. We previously reported that tissue-resident endothelial cells had 
progenitor-like capacity and were involved in tissue repair in the murine models of acute lung injury 
and pulmonary hypertension (27, 38). In the present study, EndMT-PVECs which could be involved in 
endothelial repair were derived from lung-resident cells. We focused on a mouse model in which injury 
could be repaired to better support our underlying hypothesis; it is not a severe lung injury model. With 
higher doses of LPS (15 µg/kg), we had significant mortality. Although there is a possibility that bone 
marrow-derived EndMT-PVECs could increase with more significant lung injury, in our study with 
moderate injury, bone marrow-derived EndMT-PVECs did not significantly increase while bone 
marrow-derived PVECs transiently increased at the same time in the phase of acute lung injury. 
However, it is possible that these phenomenon are dependent on the severity of injury. Taken together, 
we have to cast a spotlight on the cell transformation not only of BM-derived cells but also of 
tissue-resident cells.  
    Several limitations should be mentioned in the present study. First, we did not clearly establish the 
role of LPS-induced EndMT in any pathological process, such as post ARDS pulmonary fibrosis. Mice 
treated with LPS recovered within a week and lung inflammation regressed without any fibrotic change 
in this model. Thus, our findings demonstrated so-called 'partial EndMT,' a process in which cells 
retain reversibility to their original phenotype when stimulation ceases (49). Although partial EndMT is 
apparently associated with the development of acute lung injury in each phase, endothelial cell lineage 
tracing transgenic mice would be necessary for demonstrating 'complete EndMT' (pulmonary fibrosis), 
using a post-ARDS pulmonary fibrosis model (49). Although our murine model exhibited normal 
repair by day 7 after LPS challenge, intraperitoneal injection of LPS for three consecutive days are 
reported to induce pulmonary fibrosis (23). In such model of continuous LPS stimulation, EndMT 
might be involved not only in pulmonary fibrosis but also pathological angiogenesis as is observed in 
tumor progression (54). Indeed, LPS were reported to induce lung metastasis of breast cancer (31). 
Thus, how EndMT changes according to dose or duration of LPS or with other changes to the mouse 
model will be an issue to be investigated in the future.  
    Second, more precise assessment of gene expression associated with EndMT-PVECs is needed. In 
this study, we couldn't isolate live EndMT-PVECs because we used intracellular antigens (α-SMA and 
S100A4) as EndMT markers. Therefore further research for detecting cell-surface antigens as EndMT 
markers will be needed to elucidate the characteristics of EndMT-PVECs. 
    Third, a more rigorous evaluation of NAD(P)H oxidase isoform and/or another sources of ROS 
responsible for EndMT would be useful. These studies may provide novel insight into ROS as potential 
therapeutic targets for treatment of ALI. 
    In conclusion, our data provide the first evidence in vivo that endotoxin directly induces 
pulmonary vascular EndMT from the early phase of acute lung injury by ROS activation. The 
EndMT-PVECs share progenitor cell-like characteristics, which may contribute to repair after 
pulmonary vascular injury. Our findings are useful for further studies to elucidate the role of EndMT in 
acute lung injury, which would lead to new approaches and treatments.  
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FIGURE LEGENDS 
Figure 1. LPS-induced acute lung injury.  
(A) Body weight significantly decreased on day 2 and recovered on day 7 (*P <0.05, n = 20-96). (B) 
Extravasation of Evans Blue in murine lungs was significantly increased on day 2 (*P <0.01, n = 5). 
(C) The lung wet/dry ratio was significantly increased on day 2 (*P <0.05, n = 5). (D) Representative 
FCM panels of CD31
+
/CD45
-
 pulmonary vascular endothelial cells (PVECs) and CD31
-
/CD45
+
 
leukocytes. (E) Representative FCM panels of Gr-1
+
/CD11b
+
/CD31
-
/CD45
+
 neutrophils are shown. (F) 
The number of CD31
-
/CD45
+
 leukocytes and Gr-1
+
/CD11b
+
/CD31
-
/CD45
+
 neutrophils was 
significantly increased on day 2, but decreased reaching almost the baseline value on day 7 (*P <0.05; 
n = 6-9). Inflammatory reactions were observed in lung tissue 2 days after intraperitoneal injection of 
LPS (Hematoxylin and eosin staining, scale bar: 100 µm). (G) CD31
+
/CD45
-
 PVECs significantly 
decreased on days 1 and 2, and were almost at baseline value on day 7 (*P <0.05, **P <0.01; n = 10). 
(H) Representative FCM panels of PVECs stained with Hoechst 34580 stain. (I) The population of 
apoptotic PVECs began to increase at day 1 to day 2, then returned to base line level by day 7 (*P 
<0.05, n = 10). (J), (K) After LPS injection, oxidative stress significantly rose after 12 hours, then 
peaked after 24 hours, and eventually returned to the base line on day 7 (*P <0.05; n = 10). PVECs 
ROS production was determined by FCM using DCFDA (J) and CellRox Red (K). (A)-(C), (F), (G), 
(I)-(K) Values are means ± SEM. 
 
Figure 2. LPS induction of pulmonary vascular endothelial-to-mesenchymal transition (EndMT).  
(A) FCM analyses revealed the percentage of α-SMA+PVECs and S100A4+PVECs was significantly 
increased on day 2 after LPS challenge (*P <0.05, n = 5). Values are means ± SEM. (B) Representative 
FCM panels with α-SMA+-gated and S100A4+-gated PVECs are shown. (C) Isolated PVECs were 
immunocytochemical stained before and 2 days after LPS challenge. Time course examination by 
confocal microscopy showed few EndMT-PVECs defined as CD31
+/α-SMA+ or CD31+/S100A4+ 
before LPS challenge whereas they were noticeable on day 2. Scale bars, 20µm. (D) Gene expression 
of mesenchymal specific markers increased after LPS challenge, whereas gene expression of 
endothelial specific markers decreased after LPS challenge. Moreover, expression of transcription 
factors related to EndMT was significantly increased after LPS challenge (*P <0.05, the number of 
mice from which PVECs were isolated = 3). Values are means ± SEM. 
 
Figure 3. Characterization of EndMT-PVECs.  
(A) FCM analyses revealed higher increases in the percentage of BrdU-positive cells among 
α-SMA+PVECs compared with α-SMA-PVECs, on day 2 after LPS challenge (*P <0.05, n = 5). Values 
are means ± SEM. (B) Immunohistochemistry also revealed the presence of 
CD31
+
(green)/α-SMA+(blue) cells in capillaries on day 2 after LPS challenge (arrows). Most 
EndMT-PVECs expressed Ki67(red) (arrowheads). Yellow scale bars, 100 µm. White scale bars, 20 µm. 
(C) Histological quantification revealed that the number of Ki67
+
 cells among α-SMA+PVECs was 
higher than that in α-SMA-PVECs (*P <0.05; n = 5). Values are means ± SEM. (D) α-SMA+PVECs 
showed higher expression of EPC markers such as CD133 and c-kit (*P <0.05; n = 5). Values are 
means ± SEM. (E) Representative FCM panels of Prom1/CD133-positive cells, c-kit-positive cells and 
CD34-positive cells in α-SMA+/α-SMA-PVECs are shown. (F) Immunohistochemistry revealed higher 
expression of CD133 in α-SMA+PVECs on day 2 after LPS challenge. α-SMA: blue, CD133: red, 
α-SMA+/CD133+ : purple (arrowheads). Yellow scale bar, 100 µm. White scale bar, 20µm. (G) 
Immunohistochemistry revealed higher expression of c-kit in α-SMA+PVECs on day 2 after LPS 
challenge. α-SMA: blue, c-kit: red, α-SMA+/c-kit+: purple (arrowheads). Yellow scale bar, 100 µm. 
White scale bar, 20µm. 
 
Figure 4. Most of EndMT-PVECs originated from non-BM-derived cells. BM chimera mice 
reconstituted with GFP-expressing BM cells were analyzed by FCM to detect the origin of lung 
cells.  
Representative FCM panels of GFP
+
 peripheral blood cells (A), lung interstitial leucocytes (B), and 
PVECs (C) in control lungs are shown. GFP
-
 cells were predominant among α-SMA+PVECs before 
and after LPS challenge. (D) GFP
+
 PVECs transiently increased on day 2 after LPS challenge, and 
decreased thereafter (*P <0.05, n = 3). Values are means ± SEM. (E) Representative panels of time 
course FCM analyses related to Figure 4D. (F) GFP
-
 cells were predominant among α-SMA+PVECs 
before and after LPS challenge (comparison between GFP
+
 and GFP
-
 cells, n = 3) N.S.: Not significant. 
Values are means ± SEM. (G) Representative panels of time course FCM analyses related to Figure 4F. 
GFP
+
 cells among α-SMA+PVECs were gated and the percentage are displayed. 
 
Figure 5. Changes in α-SMA or S100A4 expression during LPS-induced EndMT depended on 
NAD(P)H oxidase activity.  
(A), (B) LY364947 (LY), apocynin (Apo), diphenyleneiodonium sulfate (DPI) and Euk-134 decreased 
dichlorofluorescein-sensitive cellular ROS (A) and CellRox Red-sensitive cellular ROS (B) in PVECs 
2 days after LPS challenge (*P <0.05 against the vehicle-treated mice, 
#
P <0.05 against the LPS-treated 
mice; n = 5). Values are means ± SEM. (C), (D) LY364947, apocynin and DPI decreased the 
percentage of α-SMA+PVECs (C) and S100A4+PVECs (D) 2 days after LPS challenge (*P <0.05 
against the vehicle-treated mice, 
$
P <0.05 against the LPS-treated mice; n = 5). Euk-134 also slightly 
decreased them, though not statistically significant. Values are means ± SEM. (E) PVECs a day after 
LPS challenge with LY364947, apocynin or DPI failed to decrease the expression of endothelial 
markers, as well as to increase the expression of mesenchymal markers. In PVECs isolated 2 days after 
LPS challenge, NAD(P)H oxidase inhibitors and LY364947 decreased the expression of Tgfb1 and 
Tgfb2 (*P <0.05; the number of mice from which PVECs were isolated = 3). Values are means ± SEM. 
 
Figure 6. LPS induced EndMT of HMVEC-L in the absence of immune cells.  
(A) Phase-contrast micrographs of HMVEC-Ls in normal growth media in the absence (upper panel) 
and presence (lower panel) of LPS (10µg/ml, for 48 hours). LPS exposure provoked morphological 
changes of HMVEC-Ls to a spindle-shape. Yellow scale bars, 300µm. Black scale bars, 50 µm. (B) 
Immunocytochemistry revealed an increase of α-SMA+HMVEC-Ls 48 hours after LPS challenge. 
Scale bars, 50µm. (C) FCM analyses also revealed the percentage of α-SMA+HMVEC-Ls was 
significantly increased 4 hours after LPS challenge (*P <0.05, n = 5). Values are means ± SEM. (D) 
Fluorescence intensity of oxidized DCFDA in viable HMVEC-Ls (PI
-
/CD31
+
/CD45
-
 cells) from 
control- and LPS-treated HMVEC-Ls with or without apocynin and LY364947 are shown. The 
fluorescence intensity increased within 2 hours of LPS challenge, which was before the increase in 
EndMT-HMVEC-Ls. These phenotypic changes were suppressed by apocynin and LY364947 (*P 
<0.05 against the vehicle-treated cells, 
$
P <0.05 against the LPS-treated cells; n = 5). Values are means 
± SEM. (E) LY364947 or apocynin decreased the percentage of α-SMA+HMVEC-Ls 48 hours after 
LPS challenge (*P <0.05, n = 5). Values are means ± SEM. (F-H) HMVEC-Ls 48 hours after LPS 
challenge with the inhibitor of TGFβ receptor 1, LY364947, or the NAD(P)H oxidase inhibitor 
apocynin failed to increase the expression of mesenchymal markers (F), failed to decrease the 
expression of endothelial markers (G), and failed to increase the expression of transcription factors 
related to EndMT (H) (*P <0.05, n = 5). Values are means ± SEM. 
 
Figure 7. EndMT-HMVEC-Ls revealed a progenitor cell-like phenotype.  
(A) FCM analyses revealed that the percentage of α-SMA+HMVEC-Ls was 40-50 % at 96 hours after 
LPS exposure and thereafter reached a plateau (*P <0.05, n = 5). Values are means ± SEM. (B) 
Representative FCM panels showing α-SMA+-gated CD31+HMVEC-Ls. (C) Quantitative PCR analysis 
of HMVEC-Ls treated with the vehicle or with LPS exposure for 144 hours was performed to evaluate 
progenitor gene expression. As a result, PROM1 and KIT were significantly upregulated in HMVEC-Ls 
subjected to LPS challenge for 144 hours (*P <0.05, n = 3). Values are means ± SEM. (D) Quantitative 
PCR analysis of HMVEC-Ls treated with the vehicle or with LPS for 144 hours was performed to 
evaluate MKI67 expression, a proliferation marker. As a result, MKI67 was significantly upregulated in 
HMVEC-Ls subjected to LPS challenge for 144 hours (*P <0.05, n = 3). Values are means ± SEM. (E) 
Quantitative PCR analysis of HMVEC-Ls was performed to evaluate drug resistance gene expression. 
As a result, ABCB1 was significantly upregulated in HMVEC-Ls subjected to LPS challenge for 144 
hours (*P <0.05, n = 5). Values are means ± SEM. (F) Quantitative PCR analysis of HMVEC-Ls was 
performed to evaluate the expression of genes related to ALDH activity. The expression of ALDH1B1 
was significantly enhanced in HMVEC-Ls subjected to LPS challenge for 144 hours (*P <0.05, n = 5). 
Values are means ± SEM. (G) Vasculogenesis assays were performed using MatrigelTM-coated slide 
chambers. HMVEC-Ls subjected to LPS challenge for 144 hours exhibited tube-like structures from 
day 1 of culture, while control HMVEC-Ls did not. Scale bars, 200 µm. 
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